Global Cutaneous T-cell Lymphoma (CTCL) Therapeutics Market To Grow At A CAGR Of 7.45% By 2028

16-Aug-2022 | Zion Market Research

The global cutaneous T-cell lymphoma (CTCL) therapeutics market size was worth around USD 1.72 billion in 2021 and is predicted to grow to around USD 2.84 billion by 2028 with a compound annual growth rate (CAGR) of roughly 7.45% between 2022 and 2028.

Lymphoma refers to cancer that has origins in cells that make up our immune system or infection-fighting cells called lymphocytes. These cells are present in the spleen, thymus, lymph nodes, bone marrow, and other body parts. In case a patient is detected with lymphoma, it means that the cells are out of control and begin attacking the healthy body cells. Lymphomas are mainly divided into two types:

Hodgkin and non-Hodgkin. Most patients with lymphoma suffer from the non-Hodgkin type. What makes lymphoma and leukemia different is the origin cell. Leukemia starts in cells that make the blood and are present in the bone marrow whereas lymphoma starts in lymphocytes. In most related cases, scientists are yet unaware of what exactly causes the disease; however, people who are more at risk are the male population, people in their 60s or above, and patients' immunity levels. T-cells are white blood cells and form a crucial part of the immunity system.

They originate from the stem cells found in the bone marrow. As a part of the infection immunity group, they work on certain foreign particles. Instead of attaching any antigen detected in the system, T-cells continue to circulate in the body until they encounter the substance they are supposed to attack. Cutaneous T-cell lymphoma is cancer-related to T-cells and even though it is not fatal in many cases like other forms of cancer, it does impact the quality of life of patients. The symptoms of lymphoma are dependent on the cancer stage. For instance, in the first stage, the signs may involve dry, patchy, red skin bumps, the second stage may follow with a skin lesion that is 1 cm or wider in width, in the third stage, the symptom may be 80% of patchy, skin and so on.

Global Cutaneous T-cell Lymphoma (CTCL) Therapeutics Market

Covid-19 had a considerable impact on the global market driven by the temporary halt in services during the initial phase of the virus. Even though complete consultation was not stopped given the seriousness of the issue, patients and doctors faced difficulty in administering treatment because of transportation restrictions along with social distancing protocol. Medicine availability was another concern owing to supply chain disruption. However, the global market picked up the pace once the facilities were functioning at full capacity.

The global cutaneous T-cell lymphoma (CTCL) therapeutics market is expected to be driven by the growing research activities in the field of cancer treatments. With all kinds of technological advancements in the medical field, there is a lack of effective treatment plans or cures for cancer even though the disease is highly prevalent across the globe.

The growing need for vaccine or drug development to treat cancer has resulted in more exhaustive research activities toward understanding the root cause of cancer and its various forms which is the stepping stone toward vaccines, drugs, or treatment development. In 2021, the USA spent over USD 187 billion on oncology research. The growth is also aided by the increase in the number of private organizations apart from pharmaceutical giants that are conducting various studies related to cancer, its types and their respective cure which is expected to propel global market growth

Non-availability of effective treatment may restrict the global market growth. A long line-up of clinical trials is expected to provide global market growth opportunities. The high cost of treatment is anticipated to challenge global market growth.

The global cutaneous T-cell lymphoma (CTCL) therapeutics market is segmented based on type, treatment, and region.

Based on type, the global market segments are Sezary syndrome and mycosis fungoides. The global market is projected to be dominated by the mycosis fungoides owing to its high prevalence as compared to the Sezary syndrome. As per the National Library of Medicine, 1 in every 100,000 to 3,50,000 people was infected by mycosis CTCL. More than 70% of T-cell lymphomas are due to this type. A lot of medicines for the treatment of both types are receiving approvals by government agencies for further use. A lot of these drugs are now called breakthrough therapy or Orphan drugs.

Based on treatment, the global market segments are chemotherapy, radiation therapy, topical therapy, immunotherapy, targeted therapy, and others. Topical therapy may generate the highest revenues in the global market owing to the rise in the number of treatment approvals, research activities, and high funding received for further development. However, chemotherapy is projected to grow at the highest CAGR because of its various applications throughout the cancer stages. The global chemotherapy market was around USD 135,400 million in 2020.

North America is anticipated to generate the highest revenue in the global cutaneous T-cell lymphoma (CTCL) therapeutics market owing to the presence of large pharmaceutical and healthcare giants aiding the research activities on cancer forms and their treatment.  The regional growth is aided by the presence of a large number of patients suffering from mycosis fungoides. As per the report published by the Cutaneous Lymphomas Foundation, more than 30,000 people in the USA live with CTCL every year.

Asia-Pacific is projected to grow significantly owing to the rise in research & development. Australia is the world’s leading country in cancer research. China and India have been investing heavily in developing medical infrastructure by conducting breakthrough research along with provisions for providing excellent medical care.

The global cutaneous T-cell lymphoma (CTCL) therapeutics market is dominated by players like Celgene Corporation, Bausch Health Companies Inc., Seattle Genetics, Kyowa Hakko Kirin Co., Ltd., Helsinn Healthcare SA, Soligenix, Inc., and Merck & Co. Inc.

Recent Development:

  • In June 2019, Innate Pharma received approval from the US Food and Drugs Administration for its IPH4102 drug which is to be used for the treatment of relapsed or refractory Sezary syndrome. The approved fast track designation aided the company in expediting the development and regulatory process of the drug.
  • In September 2021, Kyowa Kirin launched two efforts to help generate a better understanding of Sezary syndrome and mycosis fungoides, amongst patients and physicians. The programs are expected to generate higher awareness about the diseases and the available treatments.

Browse the full Global Cutaneous T-cell Lymphoma (CTCL) Therapeutics Market By Treatment (Chemotherapy, Radiation Therapy, Topical Therapy, Immunotherapy, Targeted therapy, and Others), By Type (Sezary Syndrome, and Mycosis Fungoides), and By Region - Global and Regional Industry Overview, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecasts 2022 – 2028. Report at https://www.zionmarketresearch.com/report/global-cutaneous-t-cell-lymphoma-therapeutics-market

The global cutaneous T-cell lymphoma (CTCL) therapeutics market is segmented as follows:

By Treatment

  • Chemotherapy
  • Radiation Therapy
  • Topical Therapy
  • Immunotherapy
  • Targeted therapy
  • Others

By Type

  • Sezary Syndrome
  • Mycosis Fungoides

By Region

  • North America
    • The U.S.
    • Canada
  • Europe
    • France
    • The UK
    • Spain
    • Germany
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa

About Us:

Zion Market Research is an obligated company. We create futuristic, cutting-edge, informative reports ranging from industry reports, the company reports to country reports. We provide our clients not only with market statistics unveiled by avowed private publishers and public organizations but also with vogue and newest industry reports along with pre-eminent and niche company profiles. Our database of market research reports comprises a wide variety of reports from cardinal industries. Our database is been updated constantly in order to fulfill our clients with prompt and direct online access to our database. Keeping in mind the client’s needs, we have included expert insights on global industries, products, and market trends in this database. Last but not the least, we make it our duty to ensure the success of clients connected to us—after all—if you do well, a little of the light shines on us.

Contact Us:

Zion Market Research
244 Fifth Avenue, Suite N202
New York, 10001, United States
Tel: +49-322 210 92714
USA/Canada Toll-Free No.1-855-465-4651
Email: sales@zionmarketresearch.com
Website: https://www.zionmarketresearch.com

Office Address

Contact Us

Zion Market Research
Tel: +1 (302) 444-0166
USA/Canada Toll Free No.+1 (855) 465-4651

Asia Pacific Office

3rd Floor, Mrunal Paradise, Opp Maharaja Hotel, Pimple Gurav, Pune 411061, Maharashtra, India
Phone No +91 7768 006 007, +91 7768 006 008

Contact #

US OFFICE NO +1 (302) 444-0166
US/CAN TOLL FREE +1 (855) 465-4651
Email: sales@zionmarketresearch.com

We Are On Social

Industry Press Release

We Accept

We have secured system to process your transaction.

  • payment methods

Business Hours

Our support available to help you 24 hours a day, five days a week.

Monday - Friday: 9AM - 6PM

Saturday - Sunday: Closed